Equillium, Inc. (LON:0A4D)

Market Cap	24.66M
Revenue (ttm)	34.26M
Net Income (ttm)	-3.44M
Shares Out	n/a
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,958
Average Volume	14,246
Open	0.873
Previous Close	0.920
Day's Range	0.850 - 0.880
52-Week Range	0.477 - 2.522
Beta	n/a
RSI	54.66
Earnings Date	Mar 21, 2025

About Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 44
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4D

Financial Performance

In 2023, Equillium's revenue was $36.08 million, an increase of 128.97% compared to the previous year's $15.76 million. Losses were -$13.34 million, -78.64% less than in 2022.

Financial numbers in USD